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Abstract
Neovascularization, increased basal membrane thickness and increased airway
smooth muscle (ASM) bulk are hallmarks of airway remodelling in asthma. In this
study, we examined connective tissue growth factor (CTGF) dysregulation in human
lung tissue and animal models of allergic airway disease. Immunohistochemistry
revealed that ASM cells from patients with severe asthma (A) exhibited high expres-
sion of CTGF, compared to mild and non-asthmatic (NA) tissues. This finding was
replicated in a sheep model of allergic airways disease. In vitro, transforming growth
factor (TGF)-b increased CTGF expression both in NA- and A-ASM cells but the
expression was higher in A-ASM at both the mRNA and protein level as assessed
by PCR and Western blot. Transfection of CTGF promoter-luciferase reporter con-
structs into NA- and A-ASM cells indicated that no region of the CTGF promoter
(1500 to +200 bp) displayed enhanced activity in the presence of TGF-b.
Janette K Burgess and Anthony W Ashton contributed equally.
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However, in silico analysis of the CTGF promoter suggested that distant transcrip-
tion factor binding sites may influence CTGF promoter activation by TGF-b in ASM
cells. The discord between promoter activity and mRNA expression was also
explained, in part, by differential post-transcriptional regulation in A-ASM cells due
to enhanced mRNA stability for CTGF. In patients, higher CTGF gene expression in
bronchial biopsies was correlated with increased basement membrane thickness
indicating that the enhanced CTGF expression in A-ASM may contribute to airway
remodelling in asthma.
K E YWORD S
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1 | INTRODUCTION
Asthma is a common, chronic respiratory disease affecting more than
300 million people worldwide.1 The main characteristics of asthma are
airway inflammation, airway hyper-responsiveness and airway remod-
elling.2 The structural changes in the airways, termed airway remod-
elling, include increased airway smooth muscle (ASM) bulk, increased
basal membrane thickness and vascular expansion.3,4 The extent of
airway way remodelling correlates with several clinical features of
asthma5-8 and agents that normalize the remodelling response poten-
tially improve asthma symptoms.9-11 Once considered a manifestation
of chronic inflammation, recent studies have identified remodelling is a
separate but parallel component of the asthmatic process.12
In asthma, the observed increase in ASM cell bulk and contractil-
ity directly mediates airway narrowing and is central to the process
of airway remodelling. Increased ASM number correlates with
increased reticular basement membrane (BM) thickness and
eosinophilia, but not neutrophilia.13 Further, the secretory profiles of
ASM from asthmatic patients differ significantly from those of non-
asthmatic patients suggesting that paracrine signalling from the ASM
in may have as much to do with airway remodelling as their contrac-
tile state (reviewed in Ref. [14]). Ultimately, the increased deposition
of extracellular matrix (ECM) proteins by ASM cells in asthma is key
to the airway narrowing that takes place.12,15-18 Often this is a
response to an imbalance in the cytokines/growth factors present in
their local milieu.3
In lung tissue, ASM cells are a potent source of connective tissue
growth factor (CTGF), a member of the cysteine-rich 61, CTGF,
nephroblastoma (CCN) family of proteins.19 Our previous studies
have shown greater CTGF expression in primary asthmatic (A)-ASM
cells than non-asthmatic (NA)-ASM cells after TGF-b treatment.20-22
CTGF controls ECM deposition and ultimately airway biomechanics
through changes to collagen deposition which increase ECM density
and airway stiffness.23 Indeed, the increased stiffness of the matrix
in which asthmatic ASM cells are embedded promotes a more prolif-
erative and pro-inflammatory ASM phenotype.14
The mechanisms underlying the differential regulation of CTGF
expression in A-ASM are not currently known. Studies in other
systems have reported that CTGF induction by TGF-b is regulated
through interactions of transcription factors with promoter elements
directly upstream of the promoter start site.24-27 In this study, we
investigated the mechanisms that enhance TGF-b induction of CTGF
release from A-ASM cells and the potential links to airway remod-
elling in asthma.
2 | MATERIALS AND METHODS
2.1 | Primary ASM cell isolation and culture
Approval for experiments with human lung tissue was provided by
the Ethics Review Committee of the South West Sydney Area
Health Service, St Vincent’s Hospital Sydney, Strathfield Private
Hospital, Royal Prince Alfred Hospital and the University of Sydney
Human Research Ethics Committee. Primary human ASM cells were
obtained through dissection of donated lung tissue following trans-
plantation and from endobronchial biopsies from volunteers who
provided written informed consent, as described previously.28,29 The
patients’ details are described in Table 1.
Cells were grown in 10% (v/v) foetal bovine serum (FBS) (JRH
Biosciences, Brooklyn, VIC, Australia)/high glucose Dulbecco’s modi-
fied Eagle’s medium (DMEM, Sigma-Aldrich, St. Louis, MO, USA)
containing 100 units/mL of penicillin, 100 lg/mL of streptomycin,
0.25 lg/mL of amphotericin B (Thermo Fisher, Waltham, MA, USA)
and 25 mmol/L HEPES (Sigma-Aldrich). Use of primary ASM cells
was restricted to passage numbers 2 and 8.
2.2 | Detection of CTGF by immunohistochemistry
Sections from archived paraffin-embedded lung tissue were obtained
from non-, mild and severely asthmatic patients3,4 as well as a sheep
model of allergic airways disease that had been previously
described.30 Slides were de-paraffinized in xylene and rehydrated
through graded ethanol solutions. Peroxidase-blocking solution
(DAKO, Agilent Pathology, Foster City, CA, USA) was used to block
endogenous peroxidases at 37°C for 15 minutes. Slides were
washed and incubated with serum-free protein block (DAKO) at
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37°C for 30 minutes followed by incubation with rabbit anti-CTGF
primary antibody (2.5 lg/mL for human, 5 lg/mL for sheep lung tis-
sue, ab6922; Abcam, Cambridge, UK) or rabbit IgG (same concentra-
tion as CTGF antibody, X0903, DAKO) overnight at 4°C. Primary
antibodies were diluted in REAL antibody diluent (DAKO) to mini-
mize non-specific binding. After washing, slides were incubated with
EnVision+ system HRP labelled polymer anti-rabbit secondary anti-
body (K4003, DAKO) for 45 minutes at 37°C. Liquid diaminoben-
zidine+ (DAB) substrate chromogen system (DAKO) was added and
incubated for 10 minutes at room temperature. All slides were coun-
terstained with haematoxylin (with eosin for human sections) before
dehydration through graded ethanol and mounted with dibutyl
phthalate in xylene (DPX, Tingalpa, QLD, Australia) mounting med-
ium (VWR BDH Prolabo Chemicals). Human slides were scanned
using a wide-field FL and TL microscope ZEISS Axio Scan.Z1 SlideS-
canner (Zeiss, Oberkochen, Germany), and the sheep slides were
scanned by a NDP scanner (HAMAMATSU, Hamamatsu, Japan).
2.3 | ASM cell stimulation
For all experiments, unless otherwise indicated, ASM cells were
seeded into 6-well plates at a concentration of 1 9 104 cells/cm2 in
5% (v/v) FBS/DMEM and grown for 3 days before being made quies-
cent in 0.1% (w/v) bovine serum albumin (BSA, Sigma-Aldrich, St.
Louis, MO, USA)/DMEM for 24 hours. Cells were treated with recom-
binant human TGF-b1 protein (1 ng/mL, R&D systems, Minneapolis,
MN, USA) for the indicated durations. Cells were washed twice with
ice-cold phosphate-buffered saline (PBS, Sigma-Aldrich) and lysed in
lysis buffer prior to total RNA being extracted using the ISOLATE RNA
mini kit (Bioline, London, UK) according to the manufacturer’s instruc-
tions, quantified with a NanoDrop 2000 Spectrophotometer (Nano-
Drop Technologies, Wilmington, DE, USA) and stored in 20°C for
further use. Alternately, cells were scraped into protein lysis buffer
(20 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 1 mmol/L Na2EDTA,
1 mmol/L EGTA, 1 mmol/L NaF, 20 mmol/L Na4P2O7, 2 mmol/L
Na3VO4, 1% (v/v) Triton X-100, 10% (v/v) glycerol, 0.1% (w/v) SDS,
0.5% (w/v) sodium deoxycholate, 1 mmol/L phenylmethylsulphonyl
fluoride and 1:100 Protease Inhibitor Cocktail Set III [Merck Millipore,
Billerica, MA, USA]) and stored at 20°C until analysis.
2.4 | Real-time reverse transcription polymerase
chain reaction
To investigate CTGF mRNA expression, real-time PCR was conducted
on NA- and A-ASM cells with primers and probe specific to CTGF
(Hs01026927_g1, Life Technologies, Carlsbad, CA, USA) and BioSense
SensiFastTM Probe Hi-ROX Mastermix (Bioline) using a StepOne Plus
detection system (Thermo Fisher). Relative gene expression between
treatments was calculated using the 2ΔΔCt method after normalization
against the 18s rRNA probe (4319413E-1011052, Life Technologies).
2.5 | Western blot
Total cellular protein was extracted and separated on a 10% (w/v)
SDS-PAGE gel, and transferred to polyvinylidene difluoride mem-
brane (Merck Millipore). Membranes were blocked in 5% (w/v) skim
milk in Tris-buffered saline (TBS, 20 mmol/L Tris base, 150 mmol/L
NaCl, PH7.4) containing 0.05% (v/v) Tween 20 for 30 minutes at
room temperature and incubated with goat polyclonal anti-CTGF
antibody (1:1000, sc-14939, Santa-Cruz Biotechnology, Dallas, TX,
USA) or anti-GAPDH (1:10 000, MAB-374; Millipore) at 4°C over-
night. Membranes were washed and incubated with horseradish per-
oxidase-conjugated secondary antibody (1:2000 for CTGF [P0160],
1:50 000 for GAPDH [P0161], DAKO). Images were captured using
a Kodak Image station 4000 mm, and band intensity was quantified
with Carestream MI SE software.
2.6 | CTGF promoter constructs
A Gluc-on reporter plasmid containing the full-length CTGF pro-
moter (1500 to +200 bp) driving expression of a secreted Gaussia
TABLE 1 Details of asthmatic and non-asthmatic donors
Patient Age Sex Diagnosis Sample type
1 67 Male Healthy Transplant
2 47 Male Healthy Transplant
3 22 Female Healthy Biopsy
4 64 Male ILD Transplant
5 76 Male Pulmonary cryptococcosis Resection
6 61 Female Pulmonary hypertension Transplant
7 41 Female Adenocarcinoma Resection
8 29 Male Healthy Biopsy
9 16 Male Healthy Transplant
10 65 Male Cancer Resection
11 27 Female Asthmatic Biopsy
12 54 Male Asthmatic Biopsy
13 23 Male Asthmatic Biopsy
14 58 Male Asthmatic Biopsy
15 21 Male Asthmatic Biopsy
16 38 Male Asthmatic Biopsy
17 61 Female Asthmatic Biopsy
18 85 Male Asthmatic Biopsy
19 51 Male Asthmatic Biopsy
20 63 Male Asthmatic Biopsy
21 59 Female Asthmatic Biopsy
22 64 Male Asthmatic Biopsy
23 NA NA Healthy Transplant
24 52 Male Cancer Resection
25 22 Male Healthy Biopsy
26 60 Female Cancer Resection
27 27 Male Asthmatic Biopsy
28 33 Male Asthmatic Biopsy
29 50 Male Asthmatic Biopsy
ILD, interstitial lung disease; NA, not available.
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luciferase was purchased from GeneCopoeia (Cat. HPRM25713-
PG04, Rockville, MD, USA). A series of 50 deleted constructs were
generated by PCR using the primers shown in Table 2. The full-
length CTGF promoter was excised using the restriction enzymes
Hind III and Bgl II (New England Labs, Ipswich, MA, USA) and the
generated PCR products ligated into the vector using T4 DNA ligase
(Promega, Madison, WI, USA). All constructs were sequence verified
at the Australian Genome Research Facility (Melbourne, Vic.,
Australia) prior to expansion and transfection.
2.7 | Transfection and luciferase assay
Airway smooth muscle cells and NIH-3T3 mouse embryonic fibrob-
lasts were seeded in 12-well plates at densities of 1 9 104 cells/cm2
and 8 9 104 cells per well, respectively, for 24 hours in 10% (v/v)
FBS/DMEM. The full-length CTGF promoter, or the 50 deleted con-
structs, were transfected into the indicated cells using Lipofectamine
3000 (L-3000075; Invitrogen, Carlsbad, CA, USA) transfection
reagent according to the manufacturer’s instructions using either 1
or 1.6 lg of plasmid DNA for ASM and NIH-3T3 cells, respectively.
Cells were stimulated with TGF-b1 (1 ng/mL for ASM and 10 ng/mL
for NIH-3T3) 24 hours after transfection, for a further 24 hours. The
supernatant was collected for luciferase detection by Secrete-PairTM
Dual Luminescence Assay Kit (GeneCopoeia) and total RNA isolated
from the cell monolayers using the ISOLATE RNA mini kit (Bioline)
for CTGF mRNA detection.
2.8 | Analysis of distant transcription factor binding
sites with potential to regulate CTGF promoter
To investigate other potential transcription factor binding sites in
close proximity to the CTGF promotor, H3K27Ac binding (a marker
of transcription factor binding) was investigated. This analysis was
conducted using chromatin immunoprecipitation sequence (ChIP-
Seq) data on human umbilical vein endothelial cells (HUVECs), mouse
embryonic (NIH-3T3) and normal human lung (NHLF) fibroblasts
generated as part of the Encyclopedia of DNA Elements (ENCODE)
Project (GSE29611).
2.9 | Assessment of mRNA stability in ASM cells
To measure CTGF mRNA stability, ASM cells rendered quiescent by
incubation in 0.1% (w/v) BSA/DMEM for 24 hours were treated
with TGF-b1 (1 ng/mL) for 8 hours. After washing with PBS, actino-
mycin D (10 mg/mL, Sigma-Aldrich) was added to the media for a
further 0-16 hours as indicated. Total RNA was isolated, and CTGF
mRNA was quantified by PCR as described above.
2.10 | CTGF gene expression relationship with
clinical factors
We obtained high-quality RNAseq data from 184 biopsies. Biopsies
were derived from 77 healthy individuals and 107 current or
TABLE 2 Primer sequence for CTGF 50 deletion mutant
constructs
Primer name Primer sequence (50-30)
100 forward ATC GAG ATC TAA CAA CAT AGA TTC CAA ATG A
400 forward ATC GAG ATC TGT AAT GGA ATC AGA CTT CTT A
700 forward ATC GAG ATC TAA AAC TAA GCA AGA GTT TTG G
1000 forward ATC GAG ATC TCT TCA GCT ACC TAC TTC CTA A
1300 forward ATC GAG ATC TAT GCG AGG AAT GTC CCT GTT T
Reverse primer ATC CGA GCT CGG TAC CAA GCT T
CTGF, connective tissue growth factor.
F IGURE 1 Connective tissue growth
factor (CTGF) expression is increased in
house dust mite (HDM)-induced allergic
airway disease in sheep lungs. CTGF
expression in a model of allergic airway
disease was assessed by
immunohistochemistry in HDM- and
saline-exposed (sham control) lung
segments from the same sheep30 (n = 5).
Isotype-matched negative control antibody
on serial sections shown for comparison.
Representative images shown for each
group
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former asthma patients. All patients originated from cohorts investi-
gated earlier by our research group, and a set of previously
acquired clinical data is available31,32. The study protocol was
approved by the University Medical Center Groningen medical
ethics committee. All patients gave their written informed consent.
For full patient information and details relating to RNA isolation
and sequencing, refer to Appendix S1.
A linear model was fitted to CTGF gene expression derived from
RNA sequencing in bronchial biopsies (expressed as fragments per
kilobase of transcript per million mapped reads, FPKM) as a function
of forced expiratory volume in 1 second percentage predicted
(FEV1% predicted), BM thickness, log2(PC20 to methacholine) and
log2(% of eosinophils) in sputum of asthma patients (n = 69). Age,
gender and smoking status were used as correction factors. All anal-
yses were conducted using R (version 3.3.2).
2.11 | Statistical analysis
Data were tested for normal distribution and analysed via a 2-way
analysis of variance (ANOVA) with Bonferroni post-test. A P-value
less than .05 was considered to be statistically significant (P < .05).
3 | RESULTS
3.1 | Increased CTGF expression in asthmatic lung
tissue in vivo in a sheep model and exaggerated
release of CTGF from asthmatic ASM cells in vitro
Immunohistochemistry showed that CTGF was detected in both
sham and house dust mite (HDM)-sensitized (n = 6 for both) sheep
lung tissues, and the staining was concentrated in the ASM layer
(Figure 1). Having established that asthmatic ASM shows dysregula-
tion of CTGF expression, we sought to understand the mechanism
responsible. Treatment of both asthmatic (A-) (n = 5) and non-asth-
matic (NA-) (n = 7) ASM cells with TGF-b1 induced CTGF expres-
sion (Figure 2A), confirming our previous observations.20,22 As
before, the increase of CTGF mRNA in A-ASM cells was 3- and 2.5-
fold greater than in NA-ASM cells at 12 (P < .0001) and 24 hours
(P < .05) after TGF-b1 treatment, respectively. Similar kinetics were
observed in CTGF protein expression (Figure 2B and C); however,
the magnitude of induction was greater (5- and 4-fold at 12 and
24 hours, respectively) in A- (n = 7) than NA- (n = 4) ASM cells
(P < .01).
3.2 | Transcriptional regulation of CTGF promoter
(1500 to +200 bp) is the same in asthmatic and
non-asthmatic ASM cells
Other studies have reported that CTGF expression induced by TGF-
b is regulated by an interaction between transcription factors and
CTGF promoter binding sites immediately upstream of the promoter
start site. To investigate mechanisms underlying the greater CTGF
release from A-ASM cells, compared to NA-ASM cells, after TGF-b
treatment, we transfected a full-length (1500 to + 200 bp), and a
series of 50 truncated, CTGF promoter-luciferase reporter constructs
(Figure 3A) into both A- and NA-ASM cells. The secretion of alkaline
phosphatase, driven by a CMV promoter within the constructs, was
used to normalize for transfection efficiency. Basal promoter activity
was observed with the (400 to +200 bp) construct in NA- (Fig-
ure 3B, P ≤ .05) and NA-ASM (Figure 3D; P ≤ .05) compared to the
promoter-less and (100 to +200 bp) constructs. This activity was
equivalent in A- and NA-ASM and consistent with basal CTGF
expression. The activity of the longer CTGF promoter constructs did
not differ when compared to the 400 bp construct in either NA-
(Figure 3B) or A-ASM cells (Figure 3D) suggesting basal expression
was regulated proximal to the transcriptional start site. There was
no enhancement of the CTGF promoter activity after TGF-b treat-
ment in either NA- (Figure 3B) or A- ASM cells (Figure 3D) nor did
F IGURE 2 Asthmatic airway smooth muscle (ASM) cells have
different kinetics of connective tissue growth factor (CTGF)
induction. ASM cells from A- and NA-donors were stimulated with
transforming growth factor (TGF)-b (1 ng/mL) for up to 72 h and
CTGF transcript (A; NA-ASM [n = 7] and A-ASM [n = 5]) and
protein (B; NA-ASM [n = 4] and A-ASM [n = 7]) levels examined by
Q-PCR and Western blot, respectively. Representative images of
Western blots are shown. Changes in CTGF expression by Western
blot were quantified using image J software (C). *P < .05, **P < .01
and ***P < .001 denotes significance between bovine serum
albumin and TGF-b. #P < .05, ##P < .01 and ####P < .0001, #
indicates significant difference between NA- and A-ASM cells
WANG ET AL. | 5
a new regulatory element emerge in the full-length or any of the
truncated mutants. This was in direct contrast to CTGF mRNA
expression which increased in both NA (Figure 3C)- and A (Fig-
ure 3E)-ASM cells after TGF-b treatment in the presence of all
transfections.
3.3 | Tissue specific genetic elements indicate
CTGF regulation in lung tissue is unique
To assess whether our promoter construct was indeed inducible by
TGF-b and to determine whether CTGF regulation in ASM was
F IGURE 3 Basal regulation of the connective tissue growth factor (CTGF) promoter is the same in NA- and A-ASM cells. A. Schematic of
the 50 deleted CTGF promoter constructs used to examine regulation in NA- and A-ASM cells. Different lengths of the human CTGF promoter
(1500 to +200; ) were placed upstream of a Luciferase reporter construct ( ). Secretion of alkaline phosphatase (SEAP) expression was
driven by CMV promoter in the same construct and was used as a control for transfection efficiency. Luciferase activity in conditioned media
was detected after stimulation of transfected ASM  TGF-b (1 ng/mL; NA- [B, n = 5] and A-ASM [D, n = 5]). CTGF mRNA in NA- (C) and A-
ASM (E) was measured by Q-PCR in the same cells used for luciferase assays to determine the effectiveness of induction for the endogenous
gene. “&” Denotes significance between promoter-less (0) and luciferase reporter (&P < .05, &&P < .01, &&&P < .001). *Indicates significant
difference of CTGF mRNA expression between TGF-b and BSA, *P < .05, **P < .01, ****P < .0001. ASM, asthmatic airway smooth muscle;
BSA; bovine serum albumin
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different to other tissues, we transfected NIH-3T3 cells and exam-
ined luciferase activity. Previous reports have shown that CTGF
promoter-luciferase reporter constructs increase activity 2- to 4-
fold when NIH-3T3 cells are stimulated with TGF-b.25,27,33,34
Indeed, treatment of transfected NIH-3T3 fibroblasts with TGF-b
induced a 2-fold increase in luciferase expression compared to
unstimulated cells (Figure S1) indicating our CTGF promoter con-
struct (400 to +200) was indeed inducible but just not in human
ASM cells.
Having found that the CTGF promoter regulation in human ASM
cells differed from that reported in other cell lines,25,27,33,34 we
investigated regions of transcription factor binding activity surround-
ing the CTGF transcriptional start site to look for additional regula-
tory elements. This analysis was conducted by investigating
H3K27Ac binding (a marker of transcription factor binding). For this
analysis, we used human lung fibroblasts as previously no differences
in gene expression were detected between lung fibroblasts and ASM
cells, indicating highly similar gene expression regulation.35 There
was a strong region of activity immediately upstream of the CTGF
transcriptional start site in HUVECs (1300 to 200 bp), which was
less active in human lung fibroblasts (Figure 4A). This region spanned
the 1500 bp promoter construct we had analysed (Figure 4B), and
contained several validated SMAD and TGF-b response elements
previously reported to drive CTGF expression in other species (Fig-
ure 4C, Table 3).25,27,36 However, an alternate genomic region 50 to
the (1300 to 200 bp) site (4200 to 2400 bp) showed robust
H3K27Ac binding in lung cells but relatively low activity in HUVECs
(Figure 4A). These findings suggest that this region may be responsi-
ble for the alternative regulation of CTGF expression in human lung
cells.
3.4 | CTGF mRNA stability is enhanced in
asthmatic ASM cells
Ibrul Chowdhury et al previously reported that FBS-induced CTGF
mRNA expression was regulated by both new transcription and
mRNA stabilization in primary bladder smooth muscle cells.37 To
further characterize the regulation of CTGF in A- and NA-ASM
cells, we compared the kinetics of CTGF RNA turnover induced by
TGF-b. In NA-ASM cells, CTGF transcripts were rapidly degraded,
with a half-life of 3 hours (Figure 5). In contrast, the half-life of
CTGF mRNA in A-ASM cells was prolonged (7 hours) suggesting
that the mRNA stability was enhanced in the A-ASM cells. Linear
regression showed that the degradation rate after 6 hours between
A- (k = 2.99) and NA- (k = 2.42) ASM cells was similar. How-
ever, in NA-ASM cells, the degradation of CTGF mRNA in the first
6 hours was 20.3% higher than in the A-ASM cells (k = 15.82 vs
k = 12.6, respectively) suggesting enhanced stability and slower
degradation are the source of the longer mRNA half-life in A-ASM
cells. These data suggested that TGF-b-induced CTGF mRNA in
F IGURE 4 Differential usage of promoter elements endows cell-type specific regulation of connective tissue growth factor (CTGF) in
asthmatic airway smooth muscle. A, H3K27ac profiling from human lung fibroblasts and HUVECs surrounding the CTGF gene by ChIP-Seq. B,
Plasmid CTGF promotor construct used in this project. C, Validated SMAD and transforming growth factor (TGF)-b transcription factor binding
sites across difference species. HUVECs, human umbilical vein endothelial cells; SMAD, similar to mothers against decapentaplegic. Analysis
was performed using the ENCODE database.
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A-ASM cells was more stable than NA-ASM cells providing a possi-
ble explanation for the differential expression of TGF-b-induced
CTGF between A- and NA-ASM cells.
3.5 | CTGF gene expression is unchanged in mild
asthmatic patients but relates to BM thickness
Immunohistochemical staining showed CTGF protein expression was
concentrated in the ASM area in human lung tissue, with enhanced
detection visible in asthmatic tissues, particularly from severe asthma
patients (Figure 6A). No difference in CTGF mRNA expression (Fig-
ure 6B) was detected between bronchial biopsies derived from mild
to moderately severe asthma patients (n = 69) and healthy controls
(n = 77). In addition, within asthmatic patients, we found a signifi-
cant relationship between CTGF expression and BM thickness
(b  SE 0.472  0.174, P = .008, Figure 6C) suggesting ASM-
derived CTGF expression may influence airway narrowing and
remodelling in asthma. In contrast, higher CTGF expression in asth-
matic patients was not associated with lower FEV1% predicted (Fig-
ure 6D), more severe bronchial hyper-responsiveness (Figure 6F) or
higher % eosinophil levels in sputum (Figure 6E).
4 | DISCUSSION
This is the first study that has focused on the molecular regulation
of CTGF mRNA in primary ASM cells. Tissue localization in asthmatic
airways indicated that the ASM cells were the primary location of
CTGF expression. We have shown that, unlike other cell types, regu-
lation of CTGF mRNA expression in primary ASM cells may not be
located in the first 1500 bases in the CTGF promoter, but rather lie
some distance upstream. In addition, post-transcriptional regulation
of mRNA stability plays a role in the differential TGF-b-induced
CTGF mRNA expression in A- and NA-ASM cells. CTGF expression
in asthmatic patients correlated with the degree of BM thickening,
suggesting CTGF may contribute to the mechanisms driving airway
remodelling.
In our study, we observed greater CTGF expression in airway tis-
sues taken from lung segments of sheep chronically exposed to
HDM allergen. These findings were consistent with other in vivo
studies that have reported that CTGF mRNA and protein are up-
regulated in animal models of allergic airways disease.38,39 CTGF
was also enhanced in lung tissue from severe asthmatic patients,
compared to non-asthmatic controls. The ASM cells, as the primary
source of CTGF in lung tissue, are uniquely positioned to drive
remodelling (new blood vessel formation and BM thickening) as they
lie immediately below the lamina propria, a major location of vascu-
lar expansion and ECM deposition in remodelling airways.
TABLE 3 TGF-b transcription factor binding sites across
difference species
Cells type Transcription factor
Binding site in CTGF
promoter
NIH-3T3 fibroblast Smad33,34,58 173 to 166
TGF-b responsive
element34,58
246 to 166
Ets159 126 to 77
Nucleus pulposus cells Smad26 173 to 166
C3H10T1/2 Smad25 173 to 166
Scleroderma fibroblast Smad58 173 to 166
TGF-b responsive
element58
246 to 166
Osteoblast Smad60 173 to 166
Ets142 126 to 77
CTGF, connective tissue growth factor; TGF, transforming growth factor.
F IGURE 5 Connective tissue growth factor (CTGF) mRNA
stability is enhanced in A-ASM cells. NA- (n = 4) and A-ASM cells
(n = 5) were treated with TGF-b (1 ng/mL) with actinomycin D
(10 lg/mL) added after 8 h for up to 16 h. CTGF mRNA expression
was measured by Q-PCR to assess the rate of turnover. *Means
significant difference in CTGF mRNA expression to time 0, *P < .05,
***P < .001, ****P < .0001. #P < .05 indicates a significant
difference between NA- and A-ASM. ASM, asthmatic airway smooth
muscle; TGF, transforming growth factor
F IGURE 6 Connective tissue growth factor (CTGF) expression and correlations with clinical indices in asthmatic patients. A, CTGF
expression was assessed by immunohistochemistry in human lung tissue (n = 5 for healthy control, mild asthma and severe asthma).
Representative images shown for each group. B-E, CTGF mRNA expression fragments per kilobase million (FPKM) was detected in bronchial
biopsies from healthy controls and mild asthmatic patients (B). A linear model comparing the association between CTGF expression in
asthmatic bronchial biopsies and BM thickness (lmol/L) (C), FEV1% predicted (D), % of sputum eosinophils (E) and PC20 mg/mL (F) was
conducted correcting for age, gender and smoking status. b, correlation co-efficient; P, significance value of the correlation. BM basement
membrane, FEV1% predicted forced expiratory volume in 1 s percentage predicted, PC20 the concentration of methacholine needed to
produce a 20% fall in FEV(1) from baseline. See Ref. [32] (Table 1) for lung function on this cohort
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To illuminate the cause of the difference in regulation of CTGF
mRNA between A- and NA-ASM cells, we investigated transcrip-
tional and post-transcriptional regulation of CTGF in primary ASM
cells. The well-characterized TGF-b responsive elements in the CTGF
promoter25,27,33,34 appeared to not be involved in the regulation of
CTGF in ASM cells. However, the CTGF promoter constructs used
in this study do not integrate into the chromatin. As such, the pro-
moter constructs are not subject to the same epigenetic controls as
the TGF-b responsive elements in the endogenous gene which may
account for some of the discrepancy. Our discovery of a novel CTGF
transcriptional regulatory region, upstream of what is considered to
be the core promoter region, in lung fibroblasts opens new realms in
the tissue specific regulation of CTGF expression. Given the similari-
ties in gene expression, we speculate that this mechanism is likely to
play a role in the unique regulation of CTGF in lung mesenchymal
cells; however, the absence of ASM data precluded our validation
in ASM directly and this is a limitation of our study. We have
previously shown TGF-b induced CTGF through activation of the
extracellular signal-regulated kinase (ERK) and phosphatidylinositol
3-kinase (PI3K) signalling pathways in ASM cells. ERK is known to
be linked to SMAD2/3 activation36 and likely targets the traditional
core promoter region (1300 to 200 bp) of CTGF which appears
to be SMAD sensitive (Figure 4). However, PI3K has not been asso-
ciated with SMAD 2/3 signalling to date and therefore may target
the alternative promoter regulatory region we have identified in this
study. Moreover, how these distant genomic elements are recruited
to the core promoter to modulate CTGF expression is unknown and
may be influenced by epigenetic modification of histones (particu-
larly K27 acetylation) which is readily acknowledged to be different
in asthmatic and healthy airways.40,41 Further research is necessary
to identify the transcriptional regulatory elements, potentially within
the 4200- to 2400-bp region, activated by these alternative sig-
nalling pathways for driving CTGF expression.
The similarities in basal promoter activity in A- and NA-ASM
were just as surprising as the lack of TGF-b responsiveness in the
CTGF promoter. We identified that the basal promoter in ASM is
located between 100 and 400 bp. This region contains predicted
binding sites for SMAD, AP1, TGF-b element, Ets1, NF-1-like
sequence, TIE-like site amongst others. Some of these factors have
previously been implicated in TGF-b signalling26,27,42 whilst others
have not. The similarity of basal CTGF promoter activity in A- and
NA-ASM underscores the importance of the inflammatory milieu in
the asthmatic airway in directing the phenotype of ASM during dis-
ease.
We also showed that CTGF mRNA stability was enhanced in A-
ASM cells. Chowdhury and colleagues previously showed this to be
mediated by p38 in bladder smooth muscle cells.37 However, our
previous data conclusively showed this pathway is not involved with
CTGF regulation by TGF-b in A-ASM.22 The mechanism underlying
this enhanced CTGF mRNA stability is currently unknown.
The dysregulation of CTGF in asthmatic airways may have pro-
found consequences for disease progression, as suggested by the
association of CTGF gene expression levels with BM thickening in
our patient cohort. One limitation in our study is that the biopsies
from which we obtained the gene signal were of a mixed cell pop-
ulation and we have no information about the ASM content in
each biopsy. This may have altered the CTGF gene signal as CTGF
is also expressed by airway epithelial cells and fibroblasts43-47 and
it is not known if these levels are also altered in asthma. If the
epithelial gene expression of CTGF is not increased in asthma, this
may have reduced the strength of the association we observed
with BM thickness. The BM is 2- to 3-fold thicker in asthmatic
compared to healthy airways and is associated with increased air-
way resistance, limitations to airflow and decreased lung func-
tion.48,49 Association of BM thickening with poor clinical outcome
is somewhat controversial with adults32,50 but shows better correla-
tion in children.50-52 The thicker BM of asthmatic airways also has
an altered elastic modulus compared to healthy airways.53 The
increased ECM stiffness that accompanies such a change is likely
to contribute to the pro-remodelling environment found in asth-
matic airways as stiffer matrices promote angiogenesis54,55 and
ASM cell proliferation.53 Indeed, stiffer matrices may also enhance
CTGF expression through Taz activation,56,57 completing a positive
feedback loop in the asthmatic airway that would co-ordinate all
aspects of airway remodelling (ASM bulk, neovascularization and
BM thickening).
In conclusion, our data strongly suggest that the unique regula-
tory mechanisms that underpin the enhanced CTGF expression in
A-ASM are pivotal for the development of airway remodelling. Thus,
CTGF represents an underappreciated target for future therapeutic
intervention addressing an aspect of disease pathogenesis currently
not effectively treated by existing approaches.
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